Neurology

Processing speed found to hinder MS patients in everyday life.

Depression and fatigue loom as issues to overcome for patients with multiple sclerosis.

Regular exercise may decrease MS symptoms.

MS comorbidities increase the risk of early mortality.

Salt found to influence immune cells that cause the disease.

One confirmed case and one probable case of definite progressive multifocal leukoencephalopathy reported in patients taking Gilenya for MS.

The FDA is warning health care professionals about a rare brain infection seen in multiple sclerosis patients taking fingolimod (Gilenya).

Researchers evaluate solutions to quality-of-life issues.

Decreased connectivity in network specific regions of brain at the core of cognitive changes.

Ocrelizumab may shift MS treatment paradigm.

Topical medications stimulated the regeneration of damaged brain cells.

Glatopa treats patients with relapsing forms of multiple sclerosis.

Sandoz has begun shipping glatiramer acetate (Glatopa), the first FDA-approved generic competitor to Teva's Copaxone multiple sclerosis (MS) drug.

Genetic variant found to be associated with the likelihood of patient response to interferon-beta.

Genetic variant regulates response to leading multiple sclerosis therapy.

Unbalanced gut bacteria can lead to autoimmune disorders such as type 1 diabetes, rheumatoid arthritis, and multiple sclerosis.

Drugs that activate nervous system stem cells may cause formation of new myelin.

Favorable evidence supports the drug's utility in certain psychiatric and neurological disorders.

Mitra Habibi, PharmD, a clinical pharmacist at the University of Illinois Hospital and Health Sciences System, discusses the elements of an optimal program for monitoring patients with multiple sclerosis to ensure adherence.

Miconazole and clobetasol may play a role in helping cells produce myelin.

Blocking production of specific immune cell protects against onset of MS.

Two new drugs showed significant reversal of disease severity.

Long term implications result when patients stop taking disease-modifying drugs.

Topical medications that treat skin conditions prompt stem cells in the brain to repair damage.

Pushing treatment with natalizumab from 4 weeks up to 8 weeks shows promising results.